EP0363083A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Pharmaceutical preparation for treatment of thrombocytopenic or platelet function-deficient disease
Assignee: Chugai Pharmaceutical Co Ltd
•
Filing: 1989-09-28
•
Granted: —
•
Expires: 2009-09-28
Abstract
Abstract A pharmaceutical preparation containing as an active ingredient a polypeptide having an activity of human B cell stimulating factor, for a treatment of diseases involving thrombocytonpenia or impaired platelet functions. The polypeptide can be a novel polypeptide produced by a TNK-01 cell line established from human liposarcoma, or any other polypeptides having BSF2 activity.
Inventors
- 👤 Tsukasa Abe
- 👤 Toshiro Nagasawa
- 👤 Jun-Ichi Matsushita
- 👤 Tomohiro Neichi
- 👤 Nobuo Imai
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 06:42
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/204; A61P; A61P7/00; A61P7/04
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
31 words
A pharmaceutical preparation containing as an active ingredient a polypeptide having an activity of a human B cell stimulating factor, for a treatment of diseases involving thrombocytopenia or impaired platelet functions.
Claim 2
Dependent Claim
31 words
A pharmaceutical preparation containing as an active ingredient a polypeptide having an activity of a human B cell stimulating factor, for a treatment of diseases involving thrombocytopenia or impaired platelet functions.
Claim 3
Dependent Claim
85 words
A pharmaceutical preparation according to claim 1, wherein the polypeptide is a polypeptide prepared by culturing a TNK-01 cell line established from human liposarcoma, and having the following properties: (1) having an apparent molecular weight of about 24,000 or 27,000 as determined by SDS-polyacrylamide gel electrophoresis using as molecular weight standards lysozyme (molecular weight 14,400), soy bean trypsin inhibitor (21,500), carbonic anhydrase (31,000), ovalbumin (45,000), bovine serum albumin (66,200) and phosphorylase B (92,500); and (2) having the following N-terminal amino acid sequence: (N terminal) Val-Pro-Pro-Gly-Glu-Asp-Ser-Lys-Asp-Val-Ala-Ala-Pro-His-Arg-Gln-Pro-Leu-.
Claim 4
Dependent Claim
204 words
A pharmaceutical preparation according to claim 1, wherein the polypeptide is a polypeptide having the following amino acid sequence (I): Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gln Pro Leu Thr Ser Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu Val Lys Ile Ile Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala Arg Ala Val Gln Met Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn Leu Asp Ala Ile Thr Thr Pro Asp Pro Thr Thr Asn Ala Ser Leu Leu Thr Lys Leu Gln Ala Gln Asn Gln Trp Leu Gln Asp Met Thr Thr His Leu Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg Ala Leu Arg Gln Met.
Claim 5
Dependent Claim
27 words
A pharmaceutical preparation according to claim 4, wherein the polypeptide is a polypeptide which has the amino acid sequence represented by formula (I) and has been glycosylated.
Claim 6
Dependent Claim
42 words
A pharmaceutical preparation according to claim 4, wherein the polypeptide is a polypeptide wherein one or more than one amino acid has been added to a N-terminal or C-terminal or both terminals, of the amino acid sequence represented by the formula (I).
Claim 7
Dependent Claim
36 words
A pharmaceutical preparation according to claim 4, wherein the polypeptide is a polypeptide wherein one or more than one amino acid has been deleted N-, C-terminal from the amino acid sequence represented by the formula (I).
Claim 8
Dependent Claim
44 words
A pharmaceutical preparation according to claim 4, wherein the polypeptide is a polypeptide wherein one or more than one amino acid present in the amino acid sequence represented by the formula (I) has been replaced by one or more than one other amino acid.
Claim 9
Dependent Claim
31 words
The use of a polypeptide having an activity of a human B cell stimulating factor for producing a pharmaceutical preparation for a treatment of diseases involving thrombocytopenia or impaired platelet functions.
Claim 10
Dependent Claim
31 words
The use of a polypeptide having an activity of a human B cell stimulating factor for producing a pharmaceutical preparation for a treatment of diseases involving thrombocytopenia or impaired platelet functions.
Claim 11
Dependent Claim
11 words
A cell line TNK-01 (FERM BP-2088) or mutants and derivatives thereof.
Claim 12
Dependent Claim
11 words
A cell line TNK-01 (FERM BP-2088) or mutants and derivatives thereof.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.